

ELENCO DELLE PUBBLICAZIONI

- 1)** 5-Arylidene-2,4-thiazolidinediones Inhibitors of Protein Tyrosine Phosphatases.
Maccari R, Paoli P, Ottanà R, Jacomelli M, **Ciurleo R**, Manao G, Steindl T, Langer T, Vigorita MG, Camici G.
Bioorg. Med. Chem., 2007; 15(15): 5137-49.
- 2)** Evaluation of in vitro aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.
Maccari R, Ottanà R, **Ciurleo R**, Vigorita MG, Rakowitz D, Steindl T, Langer T.
Bioorg. Med. Chem. Lett., 2007; 17(14): 3886-93.
- 3)** Synthesis and in vitro evaluation of 5-arylidene-3-hydroxyalkyl-2-phenylimino-4-thiazolidinones endowed with antidegenerative activity on human chondrocyte cultures.
Ottanà R, Maccari R, **Ciurleo R**, Vigorita MG, Panico AM, Cardile V, Garufi F, Ronisvalle S.
Bioorg. Med. Chem., 2007; 15(24): 7618-25.
- 4)** 2/4-substituted-9-fluorenones and their O-glucosides as potential immunomodulators and anti-herpes simplex virus-2 agents. Part 5.
Arena A, Arena N, **Ciurleo R**, De Gregorio A, Maccari R, Ottanà R, Pavone B, Tramice A, Trincone A, Vigorita MG.
Eur. J. Med. Chem., 2008; 43(12): 2656-64.
- 5)** Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives.
Maccari R, Ottanà R, **Ciurleo R**, Rakowitz D, Matuszczak B, Laggner C, Langer T.
Bioorg. Med. Chem., 2008; 16 (11): 5840-52.
- 6)** 5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors.
Ottanà R, Maccari R, **Ciurleo R**, Paoli P, Jacomelli M, Manao G, Camici G, Laggner C, Langer T.
Bioorg. Med. Chem., 2009; 17(5): 1928-37.
- 7)** Structure-Based Optimization of Benzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B and Low Molecular Weight Protein Tyrosine Phosphatase.
Maccari R, Ottanà R, **Ciurleo R**, Paoli P, Manao G, Camici G, Laggner C, Langer T.
ChemMedChem, 2009; 4(6): 957-63.
- 8)** Identification of new non-carboxylic acid containing inhibitors of aldose reductase.
Maccari R, **Ciurleo R**, Giglio M, Cappiello M, Moschini R, Del Corso A, Mura U, Ottanà R.
Bioorg. Med. Chem. 2010; 18(11): 4049-55.
- 9)** ¹H-MR Spectroscopy in Traumatic Brain Injury.
Marino S, **Ciurleo R**, Bramanti P, Federico A, De Stefano N.
Neurocrit Care, 2011;14 (1): 127-33.
- 10)** Neurogenic Ejaculatory Disorders: Focus on Current and Future Treatments.
Calabò RS, Polimeni G, **Ciurleo R**, Casella C, Bramanti P.
Recent Pat CNS Drug Discov. 2011; 6(3): 205-21.

11) Role of Resveratrol and its analogues in the treatment of neurodegenerative diseases: focus on recent Discoveries

Foti Cuzzola V, **Ciurleo R**, Giacoppo S, Marino S, Bramanti P.
CNS & Neurological Disorders – Drug Targets. 2011; 10(7): 849-62.

12) Diffusion-weighted imaging and fluid-attenuated inversion recovery sequence in sporadic Creutzfeldt-Jacob disease.

Morabito R, Baglieri A, **Ciurleo R**, Corallo F, De Luca R, De Salvo S, Guerrera S, Timpano F, Marino M A, Bramanti P, Marino S
Neural Regeneration Research. 2011;6(29):2295-7.

13) Magnetic resonance imaging markers for early diagnosis of Parkinson's disease.

Marino S, **Ciurleo R**, Di Lorenzo G, Barresi M, De Salvo S, Giacoppo S, Bramanti A, Lanzafame P, Bramanti P
Neural Regeneration Research. 2012;7(8): 611-9.

14) Evaluation of olfactory dysfunction in neurodegenerative diseases

Barresi M, **Ciurleo R**, Giacoppo S, Foti Cuzzola V, Celi D; Bramanti P, Marino S.
Journal of the Neurological Sciences. 2012;323(1-2):16-24.

15) Cortical reorganization in Multiple Sclerosis after intrathecal Baclofen implantation

Guerrera S, Morabito R, Baglieri A, Corallo F, **Ciurleo R**, De Luca R, De Salvo S, Marino MA, Timpano F, Bramanti P, Marino S.
Neurocase. 2014; 20(2): 225-9.

16) Persistent anosmia in a traumatic brain injury patient: Role of orbitofrontal cortex

Caminiti F, **Ciurleo R**, Bramanti P, Marino S.
Brain Injury. 2013; 27(13-14): 1715-8.

17) Pharmacotherapy for Disorders of Consciousness: Are 'Awakening' Drugs Really a Possibility?

Ciurleo R, Bramanti P, Calabro RS.
Drugs, 2013; 73: 1849-62.

18) Role of statins in the treatment of multiple sclerosis

Ciurleo R, Bramanti P, Marino S.
Pharmacol Res. 2014;87:133-43

19) Detection of olfactory dysfunction using olfactory event related potentials in young patients with multiple sclerosis.

Caminiti F, De Salvo S, De Cola MC, Russo M, Bramanti P, Marino S, **Ciurleo R**.
Plos One. 2014; 9(7): e103151.

20) Post-traumatic olfactory loss: Psychophysical, electrophysiological and neuroradiological findings in three single case studies.

Caminiti F, **Ciurleo R**, De Salvo S, Bramanti P, Marino S.
Brain Inj. 2014; 28(13-14): 1776-80.

21) Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy.

Italiano D, Bianchini E, Ilardi M, Cilia R, Pezzoli G, Zanettini R, Vacca L, Stocchi F, Bramanti P, **Ciurleo R**, Di Lorenzo G, Polimeni G, de Luise C, Ross D, Rijnbeek P, Sturkenboom M, Trifirò G. *J Neural Transm.* 2015;122(6): 799-808.

22) Magnetic Resonance Spectroscopy: An In Vivo Molecular Imaging Biomarker for Parkinson's Disease?

Ciurleo R, Di Lorenzo G, Bramanti P, Marino S.
Biomed Res Int. 2014;2014:519816.

23) Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.

Ciurleo R, Bonanno L, Lorenzo GD, Bramanti P, Marino S.
Neurosci Lett. 2015;599:55-60.

24) Effect of the antiepileptic therapy on olfactory disorders associated with mesial temporal sclerosis.

Caminiti F, De Salvo S, Nunnari D, Bramanti P, **Ciurleo R**, Granata F, Marino S.
Neurocase, 2016; 22(4):357-61.

25) Automatic Algorithm for Segmentation of Atherosclerotic Carotid Plaque.

Bonanno L, Sottile F, **Ciurleo R**, Di Lorenzo G, Bruschetta D, Bramanti A, Ascenti G, Bramanti P, Marino S. *J Stroke Cerebrovasc Dis.* 2017;26(2):411-416.

26) Functional Evaluation of Awareness in Vegetative and Minimally Conscious State.

Marino S, Bonanno L, **Ciurleo R**, Baglieri A, Morabito R, Guerrera S, Rifici C, Giorgio A, Bramanti P, De Stefano N.
Open Neuroimag J. 2017 Apr 27;11:17-25.

27) Role of diffusion tensor imaging in the diagnosis and management of post-traumatic anosmia.

Bonanno L, Marino S, De Salvo S, **Ciurleo R**, Costa A, Bruschetta D, Milardi D, Galletti F, Bramanti P, Caminiti F.
Brain Inj. 2017; 31(13-14):1964-1968

28) The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.

Russo M, Dattola V, Logiudice AL, **Ciurleo R**, Sessa E, De Luca R, Bramanti P, Bramanti A, Naro A, Calabro RS.
Medicine. 2017; 96: e8826.

29) Olfactory dysfunction as a prognostic marker for disability progression in Multiple Sclerosis: an olfactory event related potential study.

Ciurleo R, Bonanno L, De Salvo S, Romeo L, Rifici C, Sessa E, D'Aleo G, Russo M, Bramanti P, Marino S, Caminiti F. *Plos One.* 2018;13(4):e0196006.

30) Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers.

Ciurleo R, Corallo F, Bonanno L, Lo Buono V, Di Lorenzo G, Versaci R, Allone C, Palmeri R, Bramanti P, Marino S. *J Neurol.* 2018. 265(9):2005-2014

- 31)** Olfactory event-related potentials in a functionally anosmic patient with arrested hydrocephalus. Caminiti F, **Ciurleo R**, De Salvo S, Galletti F, Bramanti P, Marino S. Journal of International Medical Research. 2019; 47: 1353-1358.
- 32)** Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report
Ciurleo R, Sessa E, Marino S, D'Aleo G, Bramanti P, Rifici C. Medicine. 2019;98:e15185.
- 33)** Longitudinal analysis of brain atrophy in Alzheimer's disease and frontotemporal dementia. Marino S, Bonanno L, Lo Buono V, **Ciurleo R**, Corallo F, Morabito R, Chirico G, Marra A, Bramanti P. J Int Med Res. 2019 Oct;47(10):5019-5027.
- 34)** Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?
Cavalli E, **Ciurleo R**, Petralia MC, Fagone P, Bella R, Mangano K, Nicoletti F, Bramanti P, Basile MS. Molecules. 2020 Mar 6;25(5).
- 35)** Meta-Analysis of Transcriptomic Data of Dorsolateral Prefrontal Cortex and of Peripheral Blood Mononuclear Cells Identifies Altered Pathways in Schizophrenia.
Petralia MC, **Ciurleo R**, Saraceno A, Pennisi M, Basile MS, Fagone P, Bramanti P, Nicoletti F, Cavalli E. Genes (Basel). 2020 Apr 3;11(4).
- 36)** Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies.
Fagone P, **Ciurleo R**, Lombardo SD, Iacobello C, Palermo CI, Shoenfeld Y, Bendtzen K, Bramanti P, Nicoletti F. Autoimmun Rev. 2020:102571.
- 37)** Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.
Lanfranconi S, Scola E, Bertani GA, Zarino B, Pallini R, d'Alessandris G, Mazzon E, Marino S, Carriero MR, Scelzo E, Faragò G, Castori M, Fusco C, Petracca A, d'Agruma L, Tassi L, d'Orio P, Lampugnani MG, Nicolis EB, Vasamì A, Novelli D, Torri V, Meessen JMTA, Salman RA, Dejana E, Latini R; Treat-CCM Investigators. Trials. 2020 May 12;21(1):401.
- 38)** Nabiximols Plus Robotic Assisted Gait Training in Improving Motor Performances in People with Multiple Sclerosis.
Calabro RS, Russo M, Naro A, **Ciurleo R**, D'Aleo G, Rifici C, Balletta T, La Via C, Destro M, Bramanti P, Sessa E. Mult Scler Relat Disord. 2020;43:102177.
- 39)** Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review).
Cavalli E, Bramanti A, **Ciurleo R**, Tchorbanov AI, Giordano A, Fagone P, Belizna C, Bramanti P, Shoenfeld Y, Nicoletti F. Int J Mol Med. 2020. In press

40) The effect on deep brain stimulation of subthalamic nucleus and dopaminergic treatment in Parkinson disease.

Lo Buono V, Palmeri R, Stroscio G, Corallo F, Di Lorenzo G, Sorbera C, **Ciurleo R**, Cimino V, Bramanti P, Marino S, Bonanno L.

Medicine (Baltimore). 2020 Aug 7;99(32):e21578.

41) Effects of Combined Administration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis. Pesce A, **Ciurleo R**, Bramanti A, Armeli Iapichino EC, Petralia MC, Magro GG, Fagone P, Bramanti P, Nicoletti F, Mangano K. Molecules. 2020;25(18):E4310.

42) Anxiety, depression, and quality of life in Parkinson's disease: the implications of multidisciplinary treatment.

Lo Buono V, Palmeri R, De Salvo S, Berenati M, Greco A, **Ciurleo R**, Sorbera C, Cimino V, Corallo F, Bramanti P, Marino S, Di Lorenzo G, Bonanno L.

Neural Regen Res. 2021;16(3):587-590.

43) Comprehensive Analysis of RNA-Seq Gene Expression Profiling of Brain Transcriptomes Reveals Novel Genes, Regulators, and Pathways in Autism Spectrum Disorder. Rahman MR, Petralia MC, **Ciurleo R**, Bramanti A, Fagone P, Shahjaman M, Wu L, Sun Y, Turanli B, Arga KY, Islam MR, Islam T, Nicoletti F. Brain Sci. 2020;10(10):E747.

44) Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players. Lombardo SD, Bramanti A, **Ciurleo R**, Basile MS, Pennisi M, Bella R, Mangano K, Bramanti P, Nicoletti F, Fagone P. Oncol Lett. 2020 Dec;20(6):332.

45) Emerging Neurological and Psychobiological Aspects of COVID-19 Infection.

Tancheva L, Petralia MC, Miteva S, Dragomanova S, Solak A, Kalfin R, Lazarova M, Yarkov D, **Ciurleo R**, Cavalli E, Bramanti A, Nicoletti F.

Brain Sci. 2020 Nov 12;10(11):852.

46) Parosmia and Neurological Disorders: A Neglected Association.

Ciurleo R, De Salvo S, Bonanno L, Marino S, Bramanti P, Caminiti F.

Front Neurol. 2020 Nov 9;11:543275.

47) Multiple Sclerosis lesions detection by a hybrid Watershed-Clustering algorithm.

Bonanno L, Mammone N, De Salvo S, Bramanti A, Rifici C, Sessa E, Bramanti P, Marino S,

Ciurleo R.

Clin Imaging. 2020 Nov 5;72:162-167.

48) Hypertensive Crisis in Acute Cerebrovascular Diseases Presenting at the Emergency Department: A Narrative Review.

Cantone M, Lanza G, Puglisi V, Vinciguerra L, Mandelli J, Fisicaro F, Pennisi M, Bella R, **Ciurleo R**, Bramanti A.

Brain Sci. 2021 Jan 7;11(1):70.

49) Cognitive Decline in Rheumatoid Arthritis: Insight into the Molecular Pathogenetic Mechanisms.

Basile MS, **Ciurleo R**, Bramanti A, Petralia MC, Fagone P, Nicoletti F, Cavalli E.

Int J Mol Sci. 2021 Jan 26;22(3):1185.

50) Identification of Common Pathogenetic Processes between Schizophrenia and Diabetes Mellitus by Systems Biology Analysis.

Rahman MR, Islam T, Nicoletti F, Petralia MC, **Ciurleo R**, Fisicaro F, Pennisi M, Bramanti A, Demirtas TY, Gov E, Islam MR, Mussa BM, Moni MA, Fagone P.
Genes (Basel). 2021 Feb 7;12(2):237.

51) A Network Medicine Approach for Drug Repurposing in Duchenne Muscular Dystrophy.

Lombardo SD, Basile MS, **Ciurleo R**, Bramanti A, Arcidiacono A, Mangano K, Bramanti P, Nicoletti F, Paolo Fagone
Genes, 2021;12:543-58.

52) The impact of SARS-COV2 infection on people in residential care with Parkinson Disease or parkinsonisms: Clinical case series study.

Sorbera C, Brigandì A, Cimino V, Bonanno L, **Ciurleo R**, Bramanti P, Di Lorenzo G, Marino S.
PLoS One. 2021 May 6;16(5):e0251313.

53) The role of teriflunomide in multiple sclerosis patient: an observational study.

Corallo F, Rifici C, Bonanno L, Di Cara M, Lo Buono V, Venuti G, Marino S, **Ciurleo R**, Torre V, D'Aleo G, Bramanti P, Sessa E.
Psychol Health Med. 2021 May 27:1-8.

54) The impact of the SARS-COV2 infection on the disorder of consciousness rehabilitation unit.

Marino S, **Ciurleo R**, Todaro A, Alagna A, Logiudice AL, Corallo F, Formica C, Rifici C, Pollicino P, Caminiti F, Morini E, Bramanti P.
PLoS One. 2021 Jun 30;16(6):e0253958.

55) Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis.

Rahman MR, Islam T, Shahjaman M, Islam MR, Lombardo SD, Bramanti P, **Ciurleo R**, Bramanti A, Tchorbanov A, Fisicaro F, Fagone P, Nicoletti F, Pennisi M.
Brief Bioinform. 2021 Jul 15:bbab262.

56) Transcriptomic Data Analysis Reveals a Down-Expression of Galectin-8 in Schizophrenia Hippocampus

Petralia MC, **Ciurleo R**, Bramanti A, Bramanti P, Saraceno A, Mangano K, Quattropani MC, Nicoletti F, Fagone P.
Brain Sci. 2021;11,973

57) In Vivo Super-Resolution Track-Density Imaging for Thalamic Nuclei Identification

Basile GA, Bertino S, Bramanti A, Ciurleo R, Anastasi GP, Milardi D, Cacciola A.
Cereb Cortex. 2021 Jul 23:bhab184.

58) Ventral intermediate nucleus structural connectivity-derived segmentation: anatomical reliability and variability.

Bertino S, Basile GA, Bramanti A, **Ciurleo R**, Tisano A, Anastasi GP, Milardi D, Cacciola A.
Neuroimage. 2021 Aug 28;243:118519.

59) Striatal topographical organization: Bridging the gap between molecules, connectivity and behavior.

Basile GA, Bertino S, Bramanti A, **Ciurleo R**, Anastasi GP, Milardi D, Cacciola A
Eur J Histochem. 2021 Oct 13;65(s1).

60) Effects of diffusion signal modeling and segmentation approaches on subthalamic nucleus parcellation.

Milardi D, Basile GA, Faskowitz J, Bertino S, Quartarone A, Anastasi GP, Bramanti A, **Ciurleo R**, Cacciola A.
Neuroimage. 2022;250:118959.

61) Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study.

Bonanno L, **Ciurleo R**, Marino S, Ruvolo C, Morabito R, Bramanti A, Corallo F.
J Clin Med. 2022;11(7):1931.

62) White matter substrates of functional connectivity dynamics in the human brain.

Basile GA, Bertino S, Nozais V, Bramanti A, **Ciurleo R**, Anastasi GP, Milardi D, Cacciola A.
Neuroimage. 2022;15:119391

63) The role of brain oscillations in post-stroke motor recovery: An overview.

Leonardi G, **Ciurleo R**, Cucinotta F, Fonti B, Borzelli D, Costa L, Tisano A, Portaro S, Alito A.
Front Syst Neurosci. 2022;16:947421

64) Audit and feedback in cardio- and cerebrovascular setting: Toward a path of high reliability in Italian healthcare.

Ciurleo R, De Cola MC, Agabiti N, Di Martino M, Bramanti P, Corallo F.
Front Public Health. 2022;10:907201.

65) In vivo probabilistic atlas of white matter tracts of the human subthalamic area combining track density imaging and optimized diffusion tractography.

Basile GA, Quartu M, Bertino S, Serra MP, Trucas M, Boi M, Demontis R, Bramanti A, Anastasi GP, Milardi D, **Ciurleo R**, Cacciola A.
Brain Struct Funct. 2022;227(8):2647-2665.

66) Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.

Lanfranconi S, Scola E, Meessen JMTA, Pallini R, Bertani GA, Al-Shahi Salman R, Dejana E, Latini R; Treat_CCM Investigators.
Lancet Neurol. 2022

67) Communication Training: Significance and Effects of a Preliminary Psychological Intervention upon an Audit Team.

Cardile D, Ielo A, Corallo F, Cappadona I, D'Aleo G, De Cola MC, Bramanti P, **Ciurleo R**.
Int J Environ Res Public Health. 2023;20(5):4173.

68) Auditing the Audits: A Systematic Review on Different Procedures in Telemedicine.

Cardile D, Corallo F, Cappadona I, Ielo A, Bramanti P, Lo Buono V, **Ciurleo R**, De Cola MC.
Int J Environ Res Public Health. 2023;20(5):4484.

69) Audit as a Tool for Improving the Quality of Stroke Care: A Review.

Cappadona I, Corallo F, Cardile D, Ielo A, Bramanti P, Lo Buono V, **Ciurleo R**, D'Aleo G, De Cola MC.

Int J Environ Res Public Health. 2023;20(5):4490.

70) A&F: integrating research into practice and practice into research.

Di Blasio N, Angelici L, Bonomi A, **Ciurleo R**, Deroma L, Giusti A, Pagano E, Marchesini Reggiani G, Acampora A, Il Gruppo di Ricerca Easy-Net P.
Recenti Prog Med. 2023 Apr;118(4):196-203.

71) A&F: obstacles to implementing interventions in the health system.

Di Blasio N, Acampora A, Bonomi A, **Ciurleo R**, Deroma L, Donati S, Marchesini G.
Recenti Prog Med. 2023 Jul-Aug;114(7):432-440.

72) Ielo A, De Cola MC, Corallo F, D'Aleo G, Mento A, Cardile D, Cappadona I, Pagano M, Bramanti P, **Ciurleo R**.

Improving Knowledge of Audit and Feedback among Health Care Professionals in Sicily.
Healthcare 2023; 11: 1987.

73) De Cola MC, Ielo A, Corallo F, Pollina Addario S, Scondotto S, Allotta A, Fantaci G, Bramanti P, **Ciurleo R**.

Development of a Set of Indicators for Measuring and Improving Quality of Rehabilitation Care after Ischemic Stroke.

Healthcare 2023, 11, 2065.

74) Cardile D, Corallo F, Ielo A, Cappadona I, Pagano M, Bramanti P, D'Aleo G, **Ciurleo R**, De Cola MC.

Coping and Quality of Life Differences between Emergency and Rehabilitation Healthcare Workers.
Healthcare (Basel). 2023 Aug 9;11(16):2235.